Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Diabetes Care · 01.10.2024 · 47 (10) · 1718-1730
DOI: 10.2337/dci23-0100 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes Care, online erschienen am 30.04.2024. Verfasst von João Carlos Locatelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Human Sciences (Exercise and Sport Science), University of Western Australia, Perth, Australia. Hauptthemen laut MEDLINE: Body Composition, Incretins, Weight Loss, Resistance Training. Die Arbeit wurde bisher 169-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: National Health and Medical Research Council, Western Australian State Government.
Abstract (Originalsprache)
This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in combination with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15–24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. However, these agents also cause rapid and significant loss of lean mass (∼10% or ∼6 kg), comparable to a decade or more of aging. Maintaining muscle mass and function as humans age is crucial to avoiding sarcopenia and frailty, which are strongly linked to morbidity and mortality. Studies indicate that supervised resistance exercise training interventions with a duration >10 weeks can elicit large increases in lean mass (∼3 kg) and strength (∼25%) in men and women. After a low-calorie diet, combining aerobic exercise with liraglutide improved weight loss maintenance compared with either alone. Retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy. We propose that tailored resistance exercise training be recommended as an adjunct to incretin therapy to optimize changes in body composition by preserving lean mass while achieving fat loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Human Sciences (Exercise and Sport Science), University of Western Australia, Perth, Australia.
- Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Australia.
- Medical School, Curtin University, Perth, Australia.
- Medical School, University of Western Australia, Perth, Australia.
ORCID-Profile: Bu B Yeap, Daniel J Green
Förderung
- National Health and Medical Research Council
- Western Australian State Government
Zitieren
APA
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024). Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes Care, 47(10), 1718-1730. https://doi.org/10.2337/dci23-0100
Vancouver
Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes Care. 2024;47(10):1718-1730. doi:10.2337/dci23-0100
BibTeX
@article{Locatelli2024,
author = {Locatelli, João Carlos and Costa, Juliene Gonçalves and Haynes, Andrew and Naylor, Louise H and Fegan, P Gerry and Yeap, Bu B and Green, Daniel J},
title = {Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?},
journal = {Diabetes Care},
year = {2024},
volume = {47},
number = {10},
pages = {1718--1730},
doi = {10.2337/dci23-0100}
}
EUVIMED